N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research.

Kirsten C Morley Andrew J BaillieWim Van Den BrinkKate E ChittyKathleen BradySudie E BackDevanshi SethGreg SutherlandLorenzo LeggioPaul S Haber

Published in: Expert opinion on investigational drugs (2018)

NAC is low cost, well-tolerated and could have promise for the treatment of alcohol use disorder in the presence of liver disease. Clinical trials directly examining efficacy in this population are required.

Keyphrases

alcohol use disorder
clinical trial
low cost
machine learning
living cells
open label
fluorescent probe
phase ii